TGFB1 and neoplasm: Several tumor forms, including gliomas, breast, and prostate cancer, likely develop resistance to the tumor-suppressor effect of the TGF-β signaling pathway and instead utilize it to activate pathways that promote epithelial–mesenchymal transition (EMT), tumor invasion, metastatic spread, and immune system evasion [37,39,40].